Acute Pancreatitis Clinical Trial
Official title:
Early Feeding in Acute Pancreatitis in Children - A Randomised Controlled Trial
Acute pancreatitis (AP) in children has an increasing incidence and is at times associated
with significant morbidity and mortality. Despite this, there is no high-quality
evidence-based treatment for childhood AP and current practice is based entirely on
historical approach and extrapolation from adult studies.
In this study, we evaluate the use of early enteral feeding in children with AP. The
traditional approach to treating AP relies on fasting and intravenous fluids (or occasionally
parenteral nutrition) assuming that this minimizes stimulation of an already inflamed
pancreas. Contrary to this, evidence exists that early feeding of patients with AP may be
beneficial. Randomized controlled trials of fasting vs. early oral diet in adult patients
with mild AP, showed no differences in pain, serum amylase and CRP levels, but also shorter
hospital stay in those fed earlier. Further data in adults with severe AP demonstrated that
early enteral nutrition was associated with decreased mortality, infections and multiorgan
failure. These benefits were lost if enteral nutrition was commenced 48 hour after admission.
Suggested explanations for these findings include the possibility that enteral nutrition may
maintain integrity and function of intestinal mucosa and reduce gut-origin sepsis.
Historically, nasojejunal (NJ) feeds were felt to be safer than oral or nasogastric feeds in
the setting of AP by avoiding cephalic and gastric pancreatic stimulation. NJ feeds require
moderately invasive tube insertion under radiographic or endoscopic guidance. Recent data
suggest that oral feeding with a low fat diet was as safe as NJ feeding.
Several animal models of AP demonstrate that the exocrine pancreas is resistant to
cholecystokinin (CCK) stimulation after the onset of AP, suggesting a mechanism for the lack
of concern of exacerbating pancreatitis with enteral feeds.
Considering this data it is less certain that diet and fat restriction contribute to
treatment of AP. To further challenge the prior conceptions of AP management it is necessary
to explore the use of unrestricted diet (full fat) in mild-moderate pediatric AP, a
population with recognized low complication risk.
Despite the mounting evidence to the contrary, it is still standard clinical practice to fast
children with AP, and only slowly reintroduce feeds depending on the clinical improvement.
This is largely due to the lack of clinical interventional studies in children with AP.
This is a prospective, randomized controlled trial in children with acute pancreatitis, which
aims to demonstrate that, compared with the current standard approach of fasting with
intravenous fluids, early enteral (oral or nasogastric) feeding with standard diet or formula
will improve the following measures of outcome:
1. Length of hospital admission.
2. Serum amylase, lipase, electrolytes, calcium, magnesium, phosphate, urea, creatinine,
liver function tests, C-reactive protein (biomarker of inflammation), and full blood
count - routine blood tests performed daily until normalisation of serum lipase or until
discharge and as directed by treating clinician thereafter.
3. Weight at presentation and "ready for discharge", and at day 30 post-discharge clinic
review.
4. Systemic complications including hemodynamic instability, renal failure, intensive care
admission.
5. Analgesic requirement.
6. Local complications including pancreatic necrosis, abscess, pseudocyst.
7. Abdominal ultrasound findings during hospital admission (or other abdominal imaging as
directed by treating clinicians).
At day 30-60 post-discharge, a routine ultrasound (to assess for localized complication(s)
e.g. pseudocyst) and clinical follow-up will be undertaken.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05410795 -
Establishment and Verification of Pancreatic Volume Formula Based on Imaging
|
||
Recruiting |
NCT04195347 -
Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase
|
Phase 1/Phase 2 | |
Completed |
NCT04735055 -
Artificial Intelligence Prediction for the Severity of Acute Pancreatitis
|
||
Completed |
NCT02928718 -
The Association Between Post-ERCP Acute Pancreatitis and Various Genetic Mutations
|
||
Terminated |
NCT02885441 -
Treatment of Acute Pancreatitis With Ketorolac
|
Phase 4 | |
Completed |
NCT02563080 -
Pancreatic Exocrine Insufficiency in Acute Pancreatitis
|
||
Recruiting |
NCT01626911 -
Continuous Regional Arterial Infusion of Low Molecular Weight Heparin in Patients With Severe Acute Pancreatitis
|
N/A | |
Completed |
NCT01507766 -
The Correlations Between Early Enteral Nutrition and Intra-abdominal Pressure in Severe Acute Pancreatitis
|
Phase 4 | |
Completed |
NCT04901949 -
The Course of Acute Pancreatitis in Patients With Different BMI Groups
|
||
Recruiting |
NCT04814693 -
Conventional Endoscopic Techniques Versus EndoRotor® System for Necrosectomy of Walled of Necrosis
|
N/A | |
Completed |
NCT02743364 -
Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis
|
Phase 2 | |
Recruiting |
NCT05281458 -
Early Versus Standard Endoscopic Interventions for Peripancreatic Fluid Collections
|
N/A | |
Not yet recruiting |
NCT04990336 -
Dachaihu Decoction Compound and Rhubarb Single Medicine in the Treatment of Acute Pancreatitis
|
N/A | |
Not yet recruiting |
NCT03259880 -
Searching the Best Prognostic Factor in Out Come Evaluation in Patients With Acute Pancreatitis Admitted at Assiut University Hospitals
|
N/A | |
Completed |
NCT02543658 -
Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension
|
Phase 2 | |
Recruiting |
NCT06023771 -
Invasive Intervention of Local Complications of Acute Pancreatitis
|
||
Not yet recruiting |
NCT05501314 -
Remote Home Monitoring Acute Pancreatitis
|
N/A | |
Completed |
NCT02897206 -
Imipenem Prophylaxis in Patients With Acute Pancreatitis
|
Phase 4 | |
Recruiting |
NCT03634787 -
Heat Shock Proteins: a Pathogenic Driver and Potential Therapeutic Target in Acute Pancreatitis
|
||
Active, not recruiting |
NCT04989166 -
Effect of Nano-curcumin Supplementation in Acute Pancreatitis
|
N/A |